ASIC1/RIP1 accelerates atherosclerosis via disrupting lipophagy

• Published in: Journal of advanced research Vol. 63; pp. 195 - 206
• Main Authors: Wang, Yuan-Mei, Tang, Huang, Tang, Ya-Jie, Liu, Juan, Yin, Yu-Fang, Tang, Ya-Ling, Feng, Yao-Guang, Gu, Hong-Feng
• Format: Journal Article
• Language: English
• Published: Egypt Elsevier B.V 01.09.2024; Elsevier
• Subjects: Acid Sensing Ion Channels - metabolism; Animals; ASIC1; Atherosclerosis; Atherosclerosis - metabolism; Autophagy; GTPase-Activating Proteins; Humans; Lipid accumulation; Lipid Metabolism; Lipophagy; Macrophages - metabolism; Male; Medicine; Mice; Mice, Inbred C57BL; Mice, Knockout; Phosphorylation; RAW 264.7 Cells; RIP1; Signal Transduction; Lipid accumulation; Lipophagy; RIP1; Atherosclerosis; ASIC1
• ISSN: 2090-1232; 2090-1224; 2090-1224
• DOI: 10.1016/j.jare.2023.11.004

[Display omitted] •ASIC1 facilitates atherosclerosis via impeding lipophagy.•ASIC1 promotes RIP1 phosphorylation.•ASIC1-RIP1 interaction contributes to defective autophagy flux.•ASIC1/RIP1 facilitates lipid accumulation via inhibiting lipophagy.•ASIC1/RIP1 may be a novel target for atherosclerotic treatment. Atherosclerosis, a major contributor to cardiovascular disease, remains a significant health concern worldwide. While previous research has shown that acid-sensing ion channel 1 (ASIC1) impedes macrophage cholesterol efflux, its precise role in atherogenesis and the underlying mechanisms have remained elusive. This study aimed to investigate the role of ASIC1 in atherosclerosis and its underlying mechanisms. First, data from a single-cell RNA sequencing (scRNA-seq) database were used to explore the relationships between ASIC1 differential expression and lipophagy in human atherosclerotic lesions. Finally, we validated the role of ASIC1/RIP1 signaling in lipophagy in vivo (human and mice) and in vitro (RAW264.7 and HTP-1 cells). Our results demonstrated a significant increase in ASIC1 protein levels within CD68+ macrophages in both human aortic lesions and AopE-/- mouse lesion areas compared to nonlesion regions. Concurrently, there was a notable decrease in lipophagy, a crucial process for lipid metabolism. In vitro assays further elucidated that ASIC1 interaction with RIP1 (receptor-interacting protein 1) promoted the phosphorylation of RIP1 at serine 166 and transcription factor EB (TFEB) at serine 142, leading to disrupted lipophagy and increased lipid accumulation. Intriguingly, all these events were reversed upon ASIC1 deficiency and RIP1 inhibition. Furthermore, in ApoE-/- mouse models of atherosclerosis, silencing ASIC1 expression or inhibiting RIP1 activation not only significantly attenuated atherogenesis but also restored TFEB-mediated lipophagy in aortic tissues. This was evidenced by reduced TFEB Ser-142 phosphorylation, decreased LC3II and LAMP1 protein expression, increased numbers of lipophagosomes, and a decrease in lipid droplets. Our findings unveil the critical role of macrophage ASIC1 in interacting with RIP1 to inhibit lipophagy, thereby promoting atherogenesis. Targeting ASIC1 represents a promising therapeutic avenue for the treatment of atherosclerosis.